<div id="firstBodyDiv" data-bind-html-content-type="article" data-bind-html-compile="article.body" data-first-article-body="
Immunotherapy uses the immune system to target cancer cells killing it, and it can save lives when other treatment options, such as surgery, radiotherapy, or other treatment options fail ChemotherapyHowever, this type of treatment cannot help all patients, and some tumors can develop resistance to it.
Now oncologists have found in Britain A treatment that can reverse the cancer’s resistance to immunotherapy. They found that patients expected to die after exhausting all treatment options lived longer "Guardian".
The combination of pembrolizumab, an immunotherapy drug, and guadcitabine, a new generation of DNA methylating factor, halted the progression of cancer in more than a third of patients enrolled in the first phase of the trial. The results were published in the journal . "Immunotherapy of cancer".
Experts at the Institute of Cancer Research said the combination could become a new effective weapon against many forms of cancer.
The patients in the trial, from Royal Marsden Hospital and University College London, included patients with lung, breast, prostate and bowel cancer.
Lead researcher on the study, Professor Johan de Bono, said: "I think one of the most important things about this experiment is that we used several different methods to look for changes in the immune system, which shows very strongly that it was affected by the combination therapy.".
“>
Immunotherapy uses the immune system to target cancer cells killing it, and it can save lives when other treatment options, such as surgery, radiotherapy, or other treatment options fail ChemotherapyHowever, this type of treatment cannot help all patients, and some tumors can develop resistance to it.
Now oncologists have found in Britain A treatment that can reverse the cancer’s resistance to immunotherapy. They found that patients who were expected to die after exhausting all treatment options lived longer, according to the Guardian website.
The combination of pembrolizumab, an immunotherapy drug, and guadcitabine, a new generation of DNA methylating factor, halted the progression of cancer in more than a third of patients enrolled in the first phase of the trial. The results were published in the journal Immunotherapy of Cancer.
Experts at the Institute of Cancer Research said the combination could become a new effective weapon against many forms of cancer.
The patients in the trial, from Royal Marsden Hospital and University College London, included patients with lung, breast, prostate and bowel cancer.
“I think one of the most important things about this trial is that we used several different approaches to look for changes in the immune system, which shows very strongly that it was affected by the combination therapy,” said lead researcher Professor Johan de Bono.